<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712917</url>
  </required_header>
  <id_info>
    <org_study_id>2019/22-3</org_study_id>
    <nct_id>NCT03712917</nct_id>
  </id_info>
  <brief_title>Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine</brief_title>
  <official_title>Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine: A Randomised Parallel Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ataturk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ataturk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Preventive drug therapy in migraine aims to reduce the attack frequency, severity
      and duration of headache. Flunarizine and topiramate are widely used in the prevention of
      migraine attacks. Greater occipital nerve block (GONB) is an alternative treatment option for
      the prophylactic treatment of migraine. In this study, investigators compared the
      effectiveness of GONB, topiramate, and flunarizine in terms of reduction in post-treatment
      VAS scores and attack frequencies in patients with episodic migraine in a four-week period.

      Material and Methods: At least one hundred and twenty migraine patients are aimed to be
      randomly divided into three treatment groups, namely flunarizine (n=40, estimated),
      topiramate (n=40, estimated) and GONB (n=40, estimated). The patients will be followed up for
      four weeks and the attack frequencies and VAS scores will be recorded weekly. At the end of
      the fourth week, the response rates based on 50% and 75% or more reduction in the VAS scores
      and attack frequencies will be calculated. Group-wise comparisons will be assessed
      statistically.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>Post treatment 4 weeks</time_frame>
    <description>Range Pain 0-10, 0: No pain, 10: Worst Pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attack Frequencies</measure>
    <time_frame>Post treatment 4 weeks</time_frame>
    <description>Number of headaches patients suffer in a month.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Greater Occipital Nerve Block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼&quot; (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flunarizine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flunarizine is introduced with a single dose of 10 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Greater Occipital Nerve Block</intervention_name>
    <description>An enjection to paralyze the occipital nerve.</description>
    <arm_group_label>Greater Occipital Nerve Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>An antiepileptic agent used for migraine prophylaxis.</description>
    <arm_group_label>Topiramate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flunarizine</intervention_name>
    <description>A calcium overload blocker agent used for migraine prophylaxis.</description>
    <arm_group_label>Flunarizine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Migraine diagnosis according to ICHD-2

          2. Ages between 15 -45 Volunteering

          3. Monthly attack number between 5-14

          4. BMI between 18-30

          5. w/o history of nephrolithiasis

          6. w/o history of DM, peripheral vascular disease

          7. w/o history of chronic systemic diseases (lung, heart,liver, kidney)

          8. w/o any detected CNS disease (including MS, movement disorders, CVD, primary or
             secondary tumors)

          9. w/o history of acute or chronic psychiatric disease

         10. w/o history of antiplatelet and anticoagulant medication

         11. w/o any combination of medication overuse headache or other primary headaches

         12. w/o previous medication of flunarizine and topiramate

         13. w/o previous application of GONB

        Exclusion Criteria:

          1. Pregnancy

          2. Lost to follow up

               -  exited with his/her own will

               -  detected primary headache during follow up

               -  cessation due to adverse effects of topiramate

               -  cessation due to adverse effects of flunarizine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ataturk University Resarch Hospital</name>
      <address>
        <city>Erzurum</city>
        <zip>25000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Diener H-C, Goadsby PJ. Migraine In: Brandt T, Caplan L, Dichgans J, Diener H-C, Kennard C (eds) Course and treatment of neurological disorders. 2nd edition. Academic Press, San Diego, (2003). pp 1-16.</citation>
  </reference>
  <reference>
    <citation>Baker C. Double-blind evaluation of flunarizine and placebo in the prophylactic treatment of migraine. Headache 1987; 27:288.</citation>
  </reference>
  <reference>
    <citation>Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004 Apr;61(4):490-5.</citation>
    <PMID>15096395</PMID>
  </reference>
  <reference>
    <citation>Bovim G, Sand T. Cervicogenic headache, migraine without aura and tension-type headache. Diagnostic blockade of greater occipital and supra-orbital nerves. Pain. 1992 Oct;51(1):43-8.</citation>
    <PMID>1454403</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 13, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <results_first_submitted>November 24, 2019</results_first_submitted>
  <results_first_submitted_qc>January 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 21, 2020</results_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ataturk University</investigator_affiliation>
    <investigator_full_name>Mustafa Ceylan</investigator_full_name>
    <investigator_title>Principal İnvastigator</investigator_title>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Greater Occipital Nerve Block</keyword>
  <keyword>Topiramate</keyword>
  <keyword>Flunarizine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Flunarizine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03712917/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Greater Occipital Nerve Block</title>
          <description>The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼&quot; (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood.
Greater Occipital Nerve Block: An enjection to paralyze the occipital nerve.</description>
        </group>
        <group group_id="P2">
          <title>Topiramate</title>
          <description>Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.
Topiramate: An antiepileptic agent used for migraine prophylaxis.</description>
        </group>
        <group group_id="P3">
          <title>Flunarizine</title>
          <description>Flunarizine is introduced with a single dose of 10 mg/day.
Flunarizine: A calcium overload blocker agent used for migraine prophylaxis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Greater Occipital Nerve Block</title>
          <description>The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼&quot; (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood.
Greater Occipital Nerve Block: An enjection to paralyze the occipital nerve.</description>
        </group>
        <group group_id="B2">
          <title>Topiramate</title>
          <description>Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.
Topiramate: An antiepileptic agent used for migraine prophylaxis.</description>
        </group>
        <group group_id="B3">
          <title>Flunarizine</title>
          <description>Flunarizine is introduced with a single dose of 10 mg/day.
Flunarizine: A calcium overload blocker agent used for migraine prophylaxis.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Row population is the defined after the exclusion of patients from overall study population</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.2" spread="8.9"/>
                    <measurement group_id="B2" value="31.5" spread="8.2"/>
                    <measurement group_id="B3" value="30.9" spread="9.0"/>
                    <measurement group_id="B4" value="30.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Row population is the defined after the exclusion of patients from overall study population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Scale</title>
        <description>Range Pain 0-10, 0: No pain, 10: Worst Pain</description>
        <time_frame>Post treatment 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Greater Occipital Nerve Block</title>
            <description>The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼&quot; (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood.
Greater Occipital Nerve Block: An enjection to paralyze the occipital nerve.</description>
          </group>
          <group group_id="O2">
            <title>Topiramate</title>
            <description>Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.
Topiramate: An antiepileptic agent used for migraine prophylaxis.</description>
          </group>
          <group group_id="O3">
            <title>Flunarizine</title>
            <description>Flunarizine is introduced with a single dose of 10 mg/day.
Flunarizine: A calcium overload blocker agent used for migraine prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale</title>
          <description>Range Pain 0-10, 0: No pain, 10: Worst Pain</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pretreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="1.0"/>
                    <measurement group_id="O2" value="7.9" spread="0.9"/>
                    <measurement group_id="O3" value="7.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posttreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="1.6"/>
                    <measurement group_id="O2" value="5.5" spread="2.1"/>
                    <measurement group_id="O3" value="5.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Attack Frequencies</title>
        <description>Number of headaches patients suffer in a month.</description>
        <time_frame>Post treatment 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Greater Occipital Nerve Block</title>
            <description>The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼&quot; (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood.
Greater Occipital Nerve Block: An enjection to paralyze the occipital nerve.</description>
          </group>
          <group group_id="O2">
            <title>Topiramate</title>
            <description>Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.
Topiramate: An antiepileptic agent used for migraine prophylaxis.</description>
          </group>
          <group group_id="O3">
            <title>Flunarizine</title>
            <description>Flunarizine is introduced with a single dose of 10 mg/day.
Flunarizine: A calcium overload blocker agent used for migraine prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Attack Frequencies</title>
          <description>Number of headaches patients suffer in a month.</description>
          <units>headaches per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pretreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="2.6"/>
                    <measurement group_id="O2" value="8.0" spread="2.7"/>
                    <measurement group_id="O3" value="8.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posttreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.0"/>
                    <measurement group_id="O2" value="2.7" spread="2.3"/>
                    <measurement group_id="O3" value="2.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of the study till the end (one month)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Greater Occipital Nerve Block</title>
          <description>The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼&quot; (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood.
Greater Occipital Nerve Block: An enjection to paralyze the occipital nerve.</description>
        </group>
        <group group_id="E2">
          <title>Topiramate</title>
          <description>Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.
Topiramate: An antiepileptic agent used for migraine prophylaxis.</description>
        </group>
        <group group_id="E3">
          <title>Flunarizine</title>
          <description>Flunarizine is introduced with a single dose of 10 mg/day.
Flunarizine: A calcium overload blocker agent used for migraine prophylaxis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <description>Mild daytime sedation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fatique</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>memory difficulties</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mustafa Ceylan</name_or_title>
      <organization>Ataturk University</organization>
      <phone>+905062773216</phone>
      <email>drmuson16@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

